Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Extra £9m cash injection for growing Glasgow digital pharmacy Phlo

New funding will be used to turn the DSP into a “holistic digital healthcare” provider and expand its “footprint” across the UK, Phlo announced.

Glasgow-based digital pharmacy Phlo has secured a further £9 million in investment, it announced today (April 17).

The Scottish distance selling pharmacy (DSP) said that the capital injection would be used to “power significant scaling”, moving from digital pharmacy to “holistic digital healthcare”.

It added that in the year to come, it intends to grow “the geographic footprint of its UK operations”, expand its “technology-based partnerships” with other “health providers” and employ more people via “strategic headcount growth at all levels across the company”.

Read more: Online pharmacy Phlo secures new chief pharmacist

This marks Phlo’s second bumper funding round. In February last year, it announced a £10m “Series A” venture capital financing round, which it said would be used to “support the scaling of Phlo’s operations and their partnerships with other healthcare providers”.

It today announced that its “lead investor” for this latest round was venture capital (VC) firm Par Equity, with VC firm Thairm Bio and Scottish Enterprise - Scotland’s national economic development agency - also providing funds.

 

“Huge vote of confidence”

 

Phlo said that the investment followed a year of “robust business growth and scale”, as it launched “major new products” for women’s health, weight management and on-demand prescribing services. 

Phlo chief executive and founder Nadeem Sarwar added that the UK’s technology sector had lately been “unpredictable and incredibly challenging”, but that with their investment, Phlo’s funders had given the company “a huge vote of confidence”.

Read more: Scottish online pharmacy acquires US prescription service in 'landmark' deal

Par Equity managing partner Paul Munn said that its investment would support the digital pharmacy to become “an end-to-end digital healthcare provider in the UK”.

And Scottish Enterprise director of entrepreneurship and investment Kerry Sharp said that Phlo “fits well” with the development agency’s missions, which include supporting companies that can bring “strong economic benefits to Scotland”.

Scottish Enterprise was also among the funders in Phlo’s “Series A” round last year.

Read more: Scottish online pharmacy secures £10m cash injection to expand across UK

C+D reported in August that Phlo had secured the services of Alistair Murray as its chief pharmacist. Murray was previously the founding clinician at Echo, which was subsequently bought by Lloydspharmacy in 2019 and rebranded to LloydsDirect. 

In April 2023, Phlo announced it had bought the UK assets of US-based online prescription service Truepill for an undisclosed sum, along with Truepill UK’s business-to-business healthcare partnerships, NHS patient base and technology solutions.

And back in 2020, C+D reported on Phlo’s extraordinary crowdfunding push, when it raised £1.65m within a day of launching its campaign.

Related Content

Topics

         
Pharmacist
Oxford
£32 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD138114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel